New data on the global economic impact and burden of preventable blindness and vision impairment

NovartisTo highlight the critical need for access to eye care and regular eye examinations, Novartis and its eye care division, Alcon, are introducing new data on World Sight Day, highlighting the economic impact and burden that blindness and vision impairment can have on societies and individuals across the globe. World Sight Day, held on October 9th, is a global initiative to help raise awareness and address the problem of preventable blindness and vision impairment worldwide.

Conducted by Novartis, The European Forum Against Blindness (EFAB) and Deloitte Access Economics, "The Cost and Burden of Eye Diseases and Preventable Blindness" study quantified the economic impact of vision loss by analyzing the top four eye diseases responsible for vision loss: glaucoma, diabetic retinopathy, cataracts, and wet age-related macular degeneration (AMD), which, in the EU alone, affects one in 10 people. The study also analyzed the cost-effectiveness of interventions to prevent them. A total of 14 countries were included in the study: Australia, Argentina, Denmark, France, Germany, Ireland, Italy, Mexico, Poland, Slovak Republic, Spain, Sweden, Switzerland and the UK.

Burden and Impact of Preventable Blindness
Eyes need to be regularly examined, as many eye diseases show no early symptoms or are slow to progress and, are often only detected after vision has been altered or lost. Due to these factors, blindness and vision impairment can be a considerable burden to individuals, families and societies, imposing severe physical, financial and quality-of-life limitations.

The analysis found that within the 14 countries studied, more than 350,000 healthy life years are lost due to cataracts, glaucoma, AMD and diabetic retinopathy, equaling more than 123 million workdays lost per year. In addition, the annual economic costs due to preventable vision impairment and blindness totaled more than 20 billion EUR.

Vision Impairment and Blindness Can Be Avoided
Investing in cost-effective interventions has a big impact on reducing the disease burden. Globally, more than 285 million people live with vision impairment and blindness.[1] But, more than 90% of vision problems can be prevented, treated or cured, provided patients have access to treatment.[1]

The analysis found that access to eye care, and early diagnosis and treatment for these eye conditions can have an enormous impact on reducing the disease burden and offset a significant amount of economic cost to society. For instance, screening for diabetic retinopathy, cataracts and AMD alone can offset economic costs by more than €6 billion EUR each year. To learn more about the economic costs and burden of preventable blindness and how it differs across the globe, visit www.globalcostofblindness.com.

Taking Care of Your Eyes at Every Age
A person's eye health is constantly changing as they age, with new needs and challenges at different times in life. Eyes at age three are much different than eyes at age 30 or 60. The eyes are also a good indicator of overall health. A range of illness can be detected through an eye examination, including diabetes, high blood pressure, heart disease, and even rare hereditary diseases.[2]

This year on World Sight Day, Alcon is helping people around the world learn about their eye health at every age by providing in-depth, downloadable digital materials intended to help encourage conversations about how to properly maintain eye health and visual function. These materials cover eye diseases and conditions starting at birth to age 60 and older.

About Alcon
Alcon, the global leader in eye care, provides innovative products that enhance quality of life by helping people worldwide see better. The three Alcon businesses - Surgical, Ophthalmic Pharmaceuticals and Vision Care - offer the widest spectrum of eye care products in the world. Alcon is the second largest division of the Novartis Group, with pro-forma sales of USD 10.5 billion in 2013. Headquartered in Fort Worth, Texas, USA, Alcon has more than 25,000 employees worldwide, operations in 75 countries and products available in 180 markets.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 135,000 full-time-equivalent associates and sell products in more than 150 countries around the world.

1. International Agency for the Prevention of Blindness (IAPB), Global Facts. http://www.iapb.org/vision-2020/global-facts [Accessed October 6, 2014]
2. World Health Organization. Vision 2020: The Right to Sight. http://www.who.int/mip2001/files/1994/Vision2020-TheRighttoSight.pdf [Accessed June 26, 2014]

Most Popular Now

BioNTech's statement on patent infringement lawsui…

BioNTech SE (Nasdaq: BNTX, "BioNTech") published an official statment: "BioNTech is aware of reports that Moderna has sued Pfizer and BioNTech, alleging that COMIRNATY® i...

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...